News
The day at a glance · 2 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Intuitive Surgical Revenue Growth
22%+22%
Key driverMedical device clinical trial readouts and major pharma earnings expectations shape sector positioning ahead of quarterly results
Daily briefHealthcare· Money365.Market AI ·

Medical Device Data Drives JNJ, ABT; Earnings Queue Builds

Johnson & Johnson and Abbott report positive clinical trial results as Pfizer, Amgen, and Moderna earnings loom this week.

MedTech & Devices

Bullish
01JNJ
Johnson & Johnson (JNJ) reported positive real-world outcomes for its Impella heart pumps at the TCT 2026 meeting. Registry data from U.S. and European hospitals showed Impella use in high-risk percutaneous coronary intervention with mortality rates below prior study levels. Clinicians also reviewed ongoing PROTECT IV trial progress, which is expected to add further evidence on Impella-supported high-risk coronary procedures.
02ABT
Abbott (ABT) announced strong 30-day results from the TECTONIC Coronary Artery Disease Intravascular Lithotripsy Investigational Device Exemption Study evaluating its investigational SonicForce Coronary IVL System. The study met its primary safety and effectiveness endpoints, demonstrating outcomes in patients with severe coronary calcification. The device is designed to crack calcium buildup in coronary arteries.
03ISRG▼ -3.73%
Intuitive Surgical (ISRG) shares traded lower despite a 22% revenue increase. Analysis noted that selling surgical robots is not the largest source of the company's revenue, suggesting investor focus on the recurring revenue mix from instruments and services.
04DXCM▲ +2.95%
DexCom (DXCM) published its Q3 2026 earnings presentation. Analysis highlighted that the company's recurring sensor model synergizes with wider diabetes access thanks to Medicare, with improving patient access positioning the stock as a long-term opportunity.

Big Pharma Earnings Queue

Neutral
01PFE
Pfizer (PFE) is scheduled to report Q3 results before market open on Tuesday. The global pharmaceutical company faces investor scrutiny on its post-pandemic portfolio performance.
02AMGN
Amgen (AMGN) will report Q3 results after market hours on Tuesday. The biotech company's quarterly performance comes as the broader biotech sector has shown relative strength versus the broader market.
03MRNA
Moderna (MRNA) is scheduled to report earnings on Friday. The SITC meeting is expected to bring fresh cancer-treatment findings from Immunocore and Candel, providing broader oncology sector context alongside Moderna's results.

Oncology Focus

Neutral
01MRK
Merck (MRK) and AstraZeneca earnings commentary highlighted cancer treatment priorities. AstraZeneca emphasized ADC combinations, cell therapies and internally developed cancer vaccines as key oncology priorities. The focus on oncology buyout opportunities and cancer treatment development remains elevated across the sector.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy